ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2308

Quality of Care for Cardiovascular Disease Prevention in RA: Compliance Lipid Screening Guidelines

Timothy J Schmidt1,2, J Antonio Avina-Zubieta3,4,5, Eric C. Sayre4, Michal Abrahamowicz6, John M. Esdaile3,7,8 and Diane Lacaille9,10,11, 1Arthritis Research Centre of Canada, Richmind, BC, Canada, 2Experimental Medicine, University of British Columbia, Department of Experimental Medicine, Richmond, BC, Canada, 3Experimental Medicine, University of British Columbia, Department of Experimental Medicine, Vancouver, BC, Canada, 4Arthritis Research Centre of Canada, Richmond, BC, Canada, 5Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, 6Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada, 7Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, 8Rheumatology, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, 9Medicine, University of British Columbia, Vancouver, BC, Canada, 10Arthritis Research Centre of Canada, Vancouver, BC, Canada, 11University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, Compliance, prevention, quality of care and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Quality Measures and Quality of Care

Session Type: Abstract Submissions (ACR)

Background/Purpose: Comorbidities are increasingly recognized as significant contributors of reduced quality of life and increased mortality in RA. Cardiovascular diseases are the leading cause of premature death in RA. Previous research suggests that RA populations may receive sub-optimal care for their non-RA health related issues.

Our aim was to evaluate the quality of care for cardiovascular disease prevention in RA by measuring compliance with general population hyperlipidemia screening guidelines in RA compared to the general population.

Methods:  We conducted a retrospective matched cohort study among patients with RA who received care between Jan 1996 and Mar 2006 and followed-up until Dec 2010. RA cases were selected if they had ≥2 MD visits more than 2 mos apart with an RA code. Cases were excluded if they had ≥2 subsequent MD visits for other inflammatory arthritis; if they saw a rheumatologist and RA diagnosis was never confirmed; or if there were no subsequent RA diagnoses over a follow-up > 5 yrs (N=36,458). Controls were selected from the general population and matched 1:1 to RA cases on gender, age, and calendar year. Administrative data was obtained on all physician visits, hospital admissions, tests ordered and medications.

Outcome: Compliance with current screening guidelines for hyperlipidemia defined as testing for lipids at least once every 5 years for women ≥ 50 and men ≥ 40, excluding individuals with previous diabetes, coronary artery disease, or hyperlipidemia. Individuals’ follow-up was divided into 5-year eligibility windows, when they were eligible for the screening guideline. Each individual could contribute up to two five-year eligibility windows. Compliance was measured as the proportion of eligibility windows with at least one lipid test performed within the time period. Compliance rate between RA and controls, using eligibility windows as the unit of analysis, were compared via a GEE models to account for the lack of independence of observations obtained from the same patient, adjusting for age and gender. Compliance rate per patient was also calculated, by measuring the proportion of eligible windows per patient during follow-up when screening was performed. Mean compliance rates in the RA sample were compared to controls using a Mann-Whitney U test.

Results: We identified 13,117 individuals with RA (64.5% female, mean [SD] age 59.0 [11.3] years), contributing 5,273 five-year eligibility windows; and 14,694 controls (65.0% female, age 59.0 [11.4] years), contributing 7,228 five-year windows.  Overall, lipids were measured in 75.4% of the eligible time windows in the RA sample and in 76.7% for the control sample (OR[95% CI]=0.94 [ 0.86, 1.02], p=0.12). RA individuals met the recommended screening guidelines in 77.6% (SD= 37.5%) of their eligible time windows, compared to 78.5% (37.0%) for controls (p=0.22). 

Conclusion: In our population-based RA cohort, compliance with general population guidelines for diabetes and hyperlipidemia screening was similar in people with RA and the general population. However, given the increased prevalence and burden of cardiovascular disease, plasma glucose and lipid screening was sub-optimal for RA individuals.


Disclosure:

T. J. Schmidt,
None;

J. A. Avina-Zubieta,
None;

E. C. Sayre,
None;

M. Abrahamowicz,
None;

J. M. Esdaile,
None;

D. Lacaille,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/quality-of-care-for-cardiovascular-disease-prevention-in-ra-compliance-lipid-screening-guidelines/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology